Description
NSE Clearing Limited revises Market Wide Position Limit (MWPL) and participant/client limits for symbol HCG under the Securities Lending and Borrowing Scheme, effective March 04, 2026.
Summary
NSE Clearing Limited (NCL) has revised the Market Wide Position Limit (MWPL) and position limits for Participants, Institutional Clients, and Non-Institutional Clients for the symbol HCG under the Securities Lending and Borrowing Scheme (SLBS) for March 2026. The revision is effective from March 04, 2026, and is a partial modification of the earlier circular NCL/CMPT/73070 dated February 27, 2026.
Key Points
- Symbol HCG limits are being revised upward under the Securities Lending and Borrowing Scheme
- The revision is a partial modification of circular NCL/CMPT/73070 (February 27, 2026)
- Original framework circular: NCL/CMPT/67763 dated April 30, 2025
- All four limit categories (MWPL, Institutional, Participant, Non-Institutional) are being increased
- Effective date: March 04, 2026
Regulatory Changes
The following position limits for HCG are revised:
| Limit Type | Old Limit (Shares) | New Limit (Shares) |
|---|---|---|
| Market Wide Position Limit (MWPL) | 5,108,451 | 5,140,025 |
| Institutional Client Limit | 510,845 | 514,002 |
| Participant Limit | 510,845 | 514,002 |
| Non-Institutional Client Limit | 51,084 | 51,400 |
Compliance Requirements
- All Participants and Custodians must take note of the revised limits for HCG
- Positions in the SLBS segment for HCG must comply with the new limits effective March 04, 2026
- No action required beyond acknowledgement and system updates to reflect new limits
Important Dates
- Circular Date: March 02, 2026
- Effective Date: March 04, 2026
- Reference Circular (framework): NCL/CMPT/67763, April 30, 2025
- Prior modification circular: NCL/CMPT/73070, February 27, 2026
Impact Assessment
The revision represents a marginal upward adjustment (~0.6%) to all position limit categories for HCG in the SLBS segment. The impact is limited to participants and custodians operating in the SLBS segment for this symbol. The change reflects a routine recalibration of limits, likely based on updated free-float or share capital data for HCG. No significant market disruption or operational burden is anticipated.
Impact Justification
Routine revision of MWPL and position limits for a single symbol (HCG) in the SLBS segment; the changes are minor incremental adjustments with no broader market-wide implications.